-
Capital, M&A & Industry Strategy3 weeks agoRocket receives $150m credit facility to advance cardiovascular portfolio
The financing arrangement extends the biotechnology company’s projected operational cash runway into the third quarter of 2028 when combined with existing reserves, with further drawdowns potentially...
-
Capital, M&A & Industry Strategy3 weeks ago5 biggest venture capital raises of Q3 2026
Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced...
-
Capital, M&A & Industry Strategy3 weeks agoRougeTx: Reattaching pericytes to stabilize vessels in HHT
BIOCENTURY | EMERGING COMPANY PROFILEROUGETX: REATTACHING PERICYTES TO STABILIZE VESSELS IN HHTLeiden University Medical Center spinout raises $58M series A to take an oral small molecule into...
-
Capital, M&A & Industry Strategy3 weeks agoShionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition
Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma...
-
Capital, M&A & Industry Strategy3 weeks agoForbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and...
-
Capital, M&A & Industry Strategy3 weeks agoShionogi makes $2B rare disease play with IntraBio buy
With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick...
-
Capital, M&A & Industry Strategy3 weeks agoAstraZeneca cuts ribbon on new R&D facility in Massachusetts
AstraZeneca's has opened a new R&D centre in the biotech hotspot of Cambridge, Massachusetts, the centrepiece of a $1bn investment in the state.
-
Capital, M&A & Industry Strategy3 weeks agoSensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines
Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, aiming to...
-
Capital, M&A & Industry Strategy3 weeks agoGE HealthCare to acquire Sofie Biosciences for $945M
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.
-
Capital, M&A & Industry Strategy4 weeks agoBuilding again in rare diseases, Shionogi pays $2B for IntraBio
BIOCENTURY | DEALSBUILDING AGAIN IN RARE DISEASES, SHIONOGI PAYS $2B FOR INTRABIOAcquisition would give Japanese pharma a therapy approved for two disorders, including one first-in-disease indication
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
